SELB Selecta Biosciences Inc.

2.86
-0.05  -2%
Previous Close 2.91
Open 2.91
Price To Book -28.6
Market Cap 245,477,432
Shares 85,831,270
Volume 209,196
Short Ratio
Av. Daily Volume 527,242
Stock charts supplied by TradingView

NewsSee all news

  1. AskBio Licenses Rights to Selecta Biosciences' ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

    – Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio's AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable

  2. Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

    – Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences,

  3. Selecta Biosciences Announces $70 Million Private Placement

    WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  4. Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

    – Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company's ImmTOR™ platform – WATERTOWN,

  5. Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference

    WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim data due 1Q 2020 and full data mid-2020.
SEL-212 (COMPARE) - Head to head trial vs Krystexxa
Tophaceous gout
Grade 5 SAE reported October 17, 2018.
SEL-403
Mesothelioma

Latest News

  1. AskBio Licenses Rights to Selecta Biosciences' ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

    – Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio's AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable

  2. Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

    – Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences,

  3. Selecta Biosciences Announces $70 Million Private Placement

    WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  4. Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

    – Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company's ImmTOR™ platform – WATERTOWN,

  5. Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference

    WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  6. Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

    – Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – – Enrollment in the

  7. Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic partnership with AskBio

  8. Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call

    WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  9. Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress

    Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta's ImmTOR (SVP-Rapamycin) platformData show the addition

  10. Selecta Biosciences to Participate in Two Investor Conferences in October

    WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  11. Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer

    WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune

  12. Selecta Biosciences to Present at the Janney Healthcare Conference

    WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune